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Background
The approach taken to support individuals during the coronavirus
disease 2019 (COVID-19) pandemic needs to take into account the
requirements of people with intellectual disabilities and/or autism,
who represent a major vulnerable group, with higher rates of co-
occurring health conditions and a greater risk of dying prema-
turely. To date, little evidence on COVID-related concerns have
been produced and no report has provided structured feedback
from the point of view of peoplewith intellectual disabilities and/or
autism or of their family/carers.
Aims
To provide systemised evidence-based information of the pri-
ority concerns for people with intellectual disabilities and/or
autism regarding the COVID-19 pandemic.
Method
Senior representatives ofmajor UK-based professional and service-
user representative organisations with a stake in the care of people
with intellectual disabilities and/or autism were contacted to pro-
vide a list of concerns across three domains: ‘mental health and
challenging behaviour’, ‘physical health and epilepsy’ and ‘social
circumstances and support’. The feedback was developed into
statements on frequently reported priorities. These statements
were then rated independently by expert clinicians. A video-con-
ference meeting to reconcile outliers and to generate a consensus
statement list was held.
Results
Thirty-two organisations were contacted, of which 26 (81%)
replied. From the respondent’s data, 30 draft consensus state-
ments were generated. Following expert clinician review, there
was initially strong consensus for seven statements (23%),
increasing to 27 statements (90%) following video conferencing.
Conclusions
These recommendations highlight the expectations of people
with intellectual disabilities and/or autism in the current pan-
demic. This could support policymakers and professionals’
deliver and evidence person-centred care.
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Coronavirus disease 2019 (COVID-19), first recognised in December
2019, has led to a global pandemic posing a massive challenge for
public health, clinical research and medical professionals.1,2 There is
a clear need for a disability-inclusive response to COVID-193 and his-
torically people with intellectual and developmental disabilities (IDD),
which includes people with autism, have been underserved in public
health research initiatives.4 People with IDD have higher rates of
comorbidities associated with a poorer outcome from COVID-19
infection, including diseases of the respiratory system, circulatory
system and endocrine, nutritional and metabolic diseases, and are
also at greater risk of dying from infection, particularly in younger
age groups.5 There is a clear need for authorities to provide regular,
transparent and accessible data on COVID-19 in people with IDD,
and what such data means.6
Given the existing vulnerability of people with IDD, and their
risk of morbidity and mortality from COVID-19, concerns specific
to this population need to be identified. We aim to establish evi-
dence-based information on the priority concerns for people with
IDD during the COVID-19 pandemic, via liaison with stakeholder
groups working with this population.
Method
The methods described here were adapted from a study focusing on
maintaining the safety of people with epilepsy during the COVID-
19 pandemic.7 A STROBE checklist has been completed and sub-
mitted as it is a cross-sectional study.
Priority concerns from the IDD community were collected
through key individuals within organisations and groups. The orga-
nisations were determined through discussion among the research-
ers. Of the organisations contacted, 29 were based in England (6 of
which did not partake), as well as 2 in Ireland and 1 in Wales. The
groups included a range of professionals and experts by experience,
including healthcare professionals and carers of service users. They
were asked to report the five highest ranking concerns pertaining to
the COVID-19 pandemic in each of the following three domains:
(a) mental health and challenging behaviour;
(b) physical health and epilepsy; and
(c) social circumstances and support.
Based on the responses, ten statements relating to the most
frequently occurring priorities were formulated for each of the
three domains. These priorities were then rated by senior clinicians
(R.A., A.R., R.S. and J.W.S.) on a scale of –10 (strongly disagree)
to +10 (strongly agree). As was the case for the methodology
previously described7 recommendations rated by all clinicians as
≥+7 during the first round of rating were determined to have
attained a strong consensus. A video-conference was held between
the authors of this paper to discuss further statements for which
consensus was lacking, until a list of statements achieving strong
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consensus was reached or if not obtained the item was not included
in the final priority statement.
Ethics and participation consent
No ethical permission was required as this was done to gain knowl-
edge and attitudes as part of a consensus statement. Further, it was
with a group where consent was implicit by participation. All parti-
cipants were advised at the start that participation was voluntary
and their replies i.e. data would be analysed anonymously. We
also used the NHS Health research authority tool (http://www.
hra-decisiontools.org.uk/research/index.html), which confirmed
that no ethical approval was required.
Results
Thirty-two organisations were contacted, of which 26 (81%)
responded; Appendix 1 details a list of organisations who responded
to the request. The total number of priority concerns received was
118 for mental health and challenging behaviour, 116 for physical
health and epilepsy and 105 for social circumstances and support.
From the respondent’s data, 30 draft consensus statements were
generated, based on the most frequently recurring responses.
These draft statements were rated by the expert panel (A.R., R.A.,
R.S. and J.W.S.). Following independent consensus statement
ratings by the expert panel, a strong consensus for seven statements
(23%) was obtained, which increased to 27 statements (90%) follow-
ing statement discussion and revision via video-conference. The
resultant 27 statements for which a strong consensus was attained
are detailed below.
For the domain mental health and challenging behaviour the
priority statements were as follows.
(a) Access to mental health services.
(b) Relapse of, or further deterioration in, mental health.
(c) Risk of disruption in the usual routines of people with IDD.
(d) Relapse of, or further deterioration in, challenging behaviours.
(e) Carer strain.
(f) Over-prescription of medication.
(g) Risk of difficulties in understanding COVID-19 and/or social
distancing guidance.
(h) Risk of misattribution of symptoms and behaviours to IDD.
(i) Risk of difficulties in communication with professionals (for
example personal protective equipment, video/phone
consultations).
For the domain physical health and epilepsy the priority state-
ments were as follows.
(a) Access to physical health services.
(b) Risk of physical inactivity due to lack of professional support in
undertaking exercise.
(c) Risk stratification of individuals who need shielding.
(d) Risk of delayed presentation to services to address physical
health complaints.
(e) Risk of physical complications from possible COVID-19
infection.
(f) Risk from not monitoring epilepsy-related concerns, including
seizures and seizure-related injuries.
(g) Lack of physical health reviews and access to physical
investigations.
(h) Risk of discrimination in end-of-life care and decision-making,
including advanced care planning.
(i) Risk of lack of availability of personal protective equipment.
(j) Emergency plans for rescue medication, medication-related
concerns including drug supply and monitoring.
For the domain social circumstances and support the priority
statements were as follows.
(a) Access to social support services.
(b) Social isolation.
(c) Care staff shortages and turnover.
(d) Risk of lack of staff training.
(e) Financial hardship.
(f) Loss of respite care.
(g) Risk of abuse/neglect.
(h) Change in accommodation/breakdown of placements.
Discussion
Priorities identified can help inform allocation of resources for the
COVID-19 pandemic, as well as provide relevant information per-
tinent to potential future pandemics. They do not encompass all
potential challenges posed to the IDD community during
COVID-19, but rather highlight priority concerns for this vulner-
able group.
There is an urgent need to collect high-quality data on the
mental health effects of the COVID-19 pandemic, but this should
be guided by the priorities of the IDD community. It is essential
that the response to COVID-19 is inclusive of people with IDD,
to avoid widening pre-existing disparities for this vulnerable
group, whose specific needs are frequently overlooked.3 Our find-
ings suggest that the key concerns raised by individuals and organi-
sations including service users, family members and charities in the
field are also substantially shared by professionals. The 27 priority
statements listed may help guide the direction of COVID-19-
related research about people with IDD, as they identify what
issues appear to be important in this group. The involvement of
individuals with IDD and their carers should be embedded in all
stages of the research process, as their lived experience is
invaluable.8
Mental health and challenging behaviour
Implications for clinical practice
Individuals with IDD may be at greater risk of mental health deteri-
oration during COVID-19, for a variety of factors. These include
difficulties accessing services, restrictions brought about by lock-
down regulations and as a direct effect of fear and anxiety
brought about by the pandemic and related media coverage.8,9 An
increase in the frequency and/or intensity of challenging behaviours
may be similarly observed. COVID-19 has also brought about a sub-
stantial change in the routines of the general population, but this
may be particularly challenging for people with IDD, especially indi-
viduals with autism, who may rely on a strict daily routine to main-
tain a sense of control over their environment, maintain emotional
well-being and minimise occurrence of challenging behaviours.10
Perhaps understandably considering concerns over deterior-
ation in the mental health and challenging behaviours of people
with IDD, carer strain was also highlighted as a priority concern.
Related to this, COVID-19 has also had an impact on the level of
social support for people with IDD, including day centre care and
respite arrangements, which will subsequently further increase
carer strain.11
Over-prescription of medication is a long-standing concern
among the IDD community. Initiatives such as Stopping Over-
Medication of People with a Learning Disability (STOMP)12 have
been implemented to endeavour to reduce medication burden in
this group. During COVID-19, some non-medication-based strat-
egies to support people with IDD, such as accessing the community,
may no longer be viable. This may potentially lead to the risk of
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increasing reliance on medication strategies to support mental
health and manage challenging behaviour.
The phenomenon whereby symptoms or behaviours in people
with IDD are attributed to their underlying developmental condi-
tion rather than effectively exploring potential co-occurring phys-
ical or psychiatric conditions, has long been thought to be a
substantial obstacle to ensuring this group receive optimal care.13
There may conceivably be an increased risk of this phenomenon
during COVID-19, considering many consultations taking place
via telephone or video-conference as opposed to in person.
Implications for policy
IDD professionals should always consider the well-being of those
whom care for their patients. This is especially true during
COVID-19, where timely professional intervention could prevent
progression to the detrimental sequelae associated with carer
strain, including reduced psychological well-being14 and self-
esteem,15 as well as chronic stress.16
It is essential that medication is only prescribed where all other
viable non-medication-based strategies have been explored.17 If
there is no alternative to prescribe medication for challenging
behaviour, it is imperative that the rationale is clearly documented.
The response to medication should be regularly reviewed, with a
view to discontinuing as soon as safe to do so, in keeping with
national guidance.17
Difficulties in understanding COVID-19 and the related guid-
ance can be addressed through a number of strategies. These
include healthcare professionals providing explanations to people
with IDD during consultations, tailored to the individual’s develop-
mental level, as well as provision of accessible information designed
for this group, such as that developed by MENCAP.18
People with IDD may find the changes in consultations with
healthcare professionals particularly challenging, including remote
consultations via telephone or video-link, as well as professionals
wearing personal protective equipment. A recommendation has
been made to include several strategies to mitigate these challenges,
such as slowing down your speech, using a positive tone of voice,
affixing a photograph to your clothing and avoiding complex
sentences.19
The risks of assuming that an individual’s difficulties are
because of their IDD can be mitigated via thorough enquiry by
healthcare professionals. They should also be prepared to undertake
face-to-face consultations where diagnostic uncertainty exists, while
strictly adhering to relevant infection control rules.
Implications for research and service development
Areas for future research should focus on approaches to measure
and facilitate access to mental health services. The quality of such
care should also form a key focus, including clinicians’ prescribing
behaviours, as well as the quality of communication within and
outside of consultation settings. Research into carer experiences
can also help further delineate how the lived experience of the
COVID-19 pandemic can contribute to carer strain, helping
develop evidence-based strategies to address this issue.
Physical health and epilepsy
Implications for clinical practice
The consensus statements identify the physical health and epilepsy-
related concerns in the IDD community. As understanding of
COVID-19 evolves, there is a need to consider how this has an
impact on those with IDD. The risks are likely elevated for a
section of the IDD population based on the spectrum of comorbid
medical conditions, with increased risk of poor health outcomes.5
The most frequent concern in the physical health domain,
expressed by the stakeholder community, was access to physical
healthcare including emergency and routine care.
Emergency care is a source of difficulty for individuals, families
and carers of those with IDD needing physical health evaluations,
which has long been recognised. Barriers include discrimination
by staff and diagnostic over-shadowing.20 Numbers attending emer-
gency departments in the UK dramatically reduced during the surge
phase of the pandemic.21,22 There is a sense in the stakeholder com-
munity that fear and a sense of feeling unwelcome could result in
delayed presentations of people with IDD.
The physical complications of COVID-19 including risk of
atypical presentations of physical illness that may go initially unrec-
ognised are of concern. The impact of COVID-19 in IDD, which
could result in worsening seizure control in individuals with
poorly controlled epilepsy, is highlighted by the importance of con-
trolling fever in Dravet syndrome.
There are concerns about the medication care plans, as well as
drug supply. Given that people with IDD and epilepsy may have
an increased risk of status epilepticus, the importance of rescue
medication plans cannot be understated.23 This may terminate clus-
ters and prolonged life-threatening seizures and potentially reduce
risk of hospital admission and the possibly intensive care admission.
Drug supply was raised as a concern related to COVID-19, and this
did not seem to present itself as a major problem in terms of overall
drug supply lines.24
There is particular concern that people with IDD would face
discrimination in end-of-life care, with ventilator or intensive care
unit bed resource allocation decisions made on the basis of IDD,
which is considered a morally irrelevant factor by some.25
Implications for policy
Sufficient community resources, including specialist nursing teams,
need to be sustained to prevent spikes in avoidable admissions. This
should be factored into any decisions for staff redeployment.
The pandemic has meant routine healthcare is now largely
delivered by telephone or video consultations.26 Lack of physical
health reviews on a routine basis was a concern as they identify
unmet needs and implement interventions to improve health out-
comes. Epilepsy care has been conceivably adversely affected by
the lack of face-to-face consultations in certain situations. Vagus
nerve stimulation assessments, physical exams, assessing weight,
dental checks,27 as well as assessing biochemical and nutritional
variables (for ketogenic diet) have all been significantly more diffi-
cult to coordinate.28,29 Monitoring risk in IDD populations from
seizure-related harms and sudden unexpected death in epilepsy is
possible by telemedicine methods using validated checklists.30
There has been a lack of access to electroencephalogram diagnostic
testing in many regions, as well as epilepsy surgical programmes
having to temporarily suspend activity.
Telemedicine has advantages in that people who cannot get to
clinic or do not like travelling can be reviewed, as can various
carers or family members all simultaneously.29 The disadvantage,
however, lies in the lack of preparation and training in video assess-
ments, which may result in poor engagement.
Identifying those at highest risk from COVID is challenging as
IDD is not homogeneous and this was acknowledged by the stake-
holders. Making recommendations about shielding is challenging;
adoption of governmental guidelines is an adequate approach in
the absence of more specific evidence.31 Most expert groups have
suggested people with epilepsy for the most part will not have ele-
vated risk, and few reports have been published suggesting acute
symptomatic seizures in the context of COVID-19.32 Some
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provisional and methodologically limited Spanish data has,
however, suggested otherwise.33
This survey has highlighted concerns over a lack of opportunity
and appropriate supervision and assistance for those with IDD to
participate in exercise. The lack of physiotherapy support was men-
tioned. The sedentary behaviour and risk of weight gain could be
particularly adverse for individuals if they develop COVID-19 and
attempts to maintain physical fitness should be endorsed. Group
online solutions should be considered for feasibility. This also
applies to people with epilepsy, who have been reported to have
higher rates of sedentary behaviours.34
Healthcare settings across the UK reported shortages of per-
sonal protective equipment, and this was a concern of our stake-
holder group. This is important in private care facilities and
National Health Service hospital settings. The ability of people
with IDD to comply with use of masks for personal safety may be
problematic, which may limit socialising opportunities in the time
of emergence from the pandemic surge.
Discrimination pertaining to end-of-life care decisions
for people with IDD is likely to be subtle and covert.35 It is to be
encouraged that such decisions should be made by a multidisciplin-
ary team, including individuals with expertise in supporting and
advocating for the needs of individuals with IDD. Practitioners
should strongly consider advanced care planning where
appropriate.
Implications for research and service development
Research and service development work should focus on the
experiences and outcomes of individuals with IDDwhen requiring
emergency care during the pandemic, for complications of
COVID-19 infection, as well as unrelated physical health com-
plaints. Healthcare professionals need to measure physical-
health-related outcomes during the COVID-19 pandemic. These
include seizure frequency, admissions and mortality rates, to
understand the level of difference in such outcomes compared
with pre-COVID-19. Informed recommendations on how to
address any identified increased risks need to be developed.
Pandemic-friendly exercise interventions can be trialled, to estab-
lish how they compare with alternative approaches, or indeed, a
lack of exercise.
For individuals with IDDwho become severely unwell requiring
intensive care unit admission and/or a ventilator, their experiences
and outcomes can be compared with their non-IDD peers who
become similarly unwell. This will ascertain if there is a difference
regarding end-of-life care quality, and if so, develop strategies to
ensure effective advocacy for people with IDD.
Social circumstances and support
Implications for clinical practice
As for mental and physical health services, concerns are also
reported for social support services. The impact of reduced day
centre care and professional carer support during the COVID-19
pandemic also presents a substantial challenge to the IDD
community.
Members of the IDD community may feel increasingly
socially isolated during the pandemic. They may no longer be able
to access their regular day centre care, job or social circle, at least
not in person, with a potentially detrimental impact on their well-
being.
Concern about care staff shortages and turnover during
COVID-19 has previously been reported.36 It is essential that any
substitute caregiver is suitably educated about the individual
needs of the person with IDDwhom they are caring for, to minimise
the impact of such a change. Even with optimal transitions of care,
however, there may be a detrimental impact on the individual with
IDD, as previous findings have shown continuity of care to be sig-
nificantly associated with their quality of life.37 This is linked to con-
cerns that staff may be inadequately trained, as well as concerns of a
lack of COVID-19-specific training for care staff. COVID-19-spe-
cific training can be provided locally, as well as utilising freely avail-
able online training, such as that provided by the World Health
Organization.38
Loss of respite care during COVID-19 has a detrimental effect
on carers of people with IDD, who may have benefited substantially
from such breaks in care with regard to their mental health and
overall well-being.39 Individuals with IDD may also suffer from
the consequences of a loss of respite care, such as from the disrup-
tion to their routine from not attending or indirectly from their
regular carer’s impaired ability to care for them as a result of
increased carer strain.
People with IDD may be especially vulnerable to abuse during
the COVID-19 pandemic as usual community-based support
sources (such as family members and mental health professionals)
may not be available because of social distancing.39
Some individuals with IDD may experience a change in their
accommodation during COVID-19. This may be moving from a
more crowded residential care setting back into the family home,
with a view to reducing likelihood of infection. This may,
however, have unintended detrimental consequences resulting
from the departure from familiar routine for the individual with
IDD, as well as the family having a lack of experience in caring
for them for prolonged periods of time. Equally, care home place-
ments may breakdown during the COVID-19 pandemic, likely as
a consequence of a multitude of factors, including deterioration in
mental health and challenging behaviours, disruption of routine,
high staff turnover and social isolation, among others. This
concern has been previously raised.39,40 IDD professionals have a
collective responsibility to address proactively such situations and
prevent placements where people under their care had been previ-
ously functioning well from collapsing.
Implications for policy
Concerns have previously been reported about professionals
working in the IDD sector potentially being redeployed to other ser-
vices during the pandemic.41 We share these concerns, as even prior
to COVID-19, people with IDD were a substantially marginalised
group who experienced significant barriers to mental, physical
and social support. It is imperative that they do not experience
further such discrimination at a time when their support needs
are likely to be substantially increased.41
Digital communication presents a crucial tool in maintaining
contact with loved ones, and people with IDD need to be supported
to ensure that they can use such technology in order to maintain
crucial relationships during the pandemic.42
There are understandable concerns about financial hardship for
people with IDD during COVID-19, as well as for their care provi-
ders. For patient-facing third-sector organizations such as charities,
particularly those that represent vulnerable and marginalised
groups like those with intellectual disability, the World Health
Organization recommend that the government provide sustainabil-
ity grants to help continue their core work of representation of the
groups they support.38
Implications for research and service development
Areas for further study in this aspect of care should focus on the
experiences of people with IDD during the pandemic, particularly
related to social isolation, with a view to developing strategies to
maintain social inclusion during such challenging circumstances.
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One option may be to explore virtual technologies as a means of
enabling groups of people with IDD to communicate with one
another and/or with carers remotely. This could include videotel-
ephony; as such services have received positive feedback in focus
groups for people with IDD, who report an increased sense of secur-
ity and safety.43 Handover processes for carers should also be
reviewed, to ensure that people with IDD are being cared for by
individuals with an in-depth knowledge of their specific care needs.
Pandemic-related factors that likely contribute to placement
breakdown, such as loss of respite care and high staff turnover
should be researched thoroughly. This is required to establish
what strategies can be employed in a pandemic situation to rescue
placements where persons with IDD were previously functioning
well. Additionally, where different forms of financial support for
carers and persons with IDD are given, these can be analysed and
compared to establish their efficacy in improving/maintaining the
quality of lives of the recipients. This should also be used to establish
what approach brings about the greatest reward per unit of
investment.
Limitations
Members of the IDD community as well as their corresponding
organisations were almost all based in England (29 of the 32 orga-
nisations invited to take part). As a result, one cannot be certain
as to whether the priority concerns identified here are generalisable
to the UK, or indeed from an international perspective.
A further limitation is that the expert panel solely comprised
healthcare professionals. Ideally, individuals with IDD and carers
should have also been part of this panel, to ensure representation
in all stages process, and avoid the potential for healthcare profes-
sionals to have too great an influence over the development of the
resulting consensus statements.
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Appendix
List of responding organisations
Organisation
Alder Hey Children’s Hospital
Ancora Medical Practice
Association of Chartered Physiotherapists for People with Learning
Disabilities
British Dietetic Association
Child and Young Person’s Clinical Psychology Network
Cork University Hospital
Epilepsy Action
Epilepsy Ireland
Epilepsy Nurses Association
Epilepsy Society
Epilepsy Sparks
International League Against Epilepsy
Learning Disability Professional Senate
Medicines Safety in Neurodiversity
Pennine Care NHS Foundation Trust
Radiant Research Consortium
Royal College of General Practitioners
Royal College of Occupational Therapists, Specialist Section, People with
Learning Disabilities
Royal College of Psychiatrists
Royal College of Speech and Language Therapists
Royal Mencap Society
Royal Society of Medicine
SUDEP Action
Swansea Bay UHB
UCL Queen Square Institute of Neurology, Department of Experimental &
Clinical Epilepsy
Young Epilepsy
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